Teva Pharma (TEVA) Tops Q2 EPS by 5c; Guides In-Line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Teva Pharma (TEVA) Tops Q2 EPS by 5c; Guides In-Line
August 8, 2016 6:53 AM EDT
Mizuho Securities maintained a Buy rating on Teva Pharma (NYSE: TEVA), and cut the price target to $70.00 (from $75.00), following the company's 2Q earnings report. TEVA reported revenue of $5.0B and $1.25 EPS, vs. $4.88B and $1.20 consensus and management's recent guidance of $4.9- $5.0B and... More
August 5, 2016 9:03 AM EDT
Piper Jaffray analyst David Amsellem bumped his price target on Teva Pharma (NYSE: TEVA) to $57.00 (from $55.00) but maintained a Neutral rating following Q2 results.
Amsellem commented, "Teva reported 2Q16 non-GAAP diluted EPS of $1.25 on revenue of $5.04B; recall that the company pre-announced... More
August 5, 2016 7:27 AM EDT
Oppenheimer downgraded Teva Pharma (NYSE: TEVA) from Outperform to Perform and removed its price target (prior $72.00).
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $55.45 yesterday.
...
More
